Test & Treat
Looking to collaborate?No
What does your test detect?
What infection type does your test focus on?
What is the technological basis of your test?
About this entry
The technology is designed for point of care use, such that the physician can detect (Test1: Sensitivity 97.1%, Specificity 92%) a UTI in 5 mins then (Test2) confidently prescribe a suitable antibiotic to treat the identified infection whilst the patient is present. Data indicates 30% of patients (human Medical Centre clinical evaluation data) treated empirically ( a mix of infection-resistant first antibiotic prescribing and UTI-negative patients who are treated inappropriately) would benefit from adoption of the Test&Treat technology.
Test&Treat technology provides quantitative antibiotic susceptibility in 30mins (with sensitivity and specificity >90%) on first line antibiotic treatment of UTI. The technology, based on ATP bioluminescence, is now being commercialised in partnership with Abtek Biologicals, Liverpool.
Test&Treat is a UK limited company, formed September 2017 (Company Number 10971513).